Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

被引:218
|
作者
Wali, M
Harrison, RF
Gow, PJ
Mutimer, D [1 ]
机构
[1] Queen Elizabeth Hosp, Liver & Hepatobiliary Unit, Birmingham B15 2TH, W Midlands, England
[2] Univ Birmingham, Dept Med, Birmingham, W Midlands, England
[3] Univ Birmingham, Dept Pathol, Birmingham, W Midlands, England
关键词
D O I
10.1136/gut.51.2.248
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Cirrhosis with liver failure due to hepatitis C virus (HCV) infection is the most common indication for liver transplantation (LT). Reinfection of the transplanted liver by HCV is inevitable, and aggressive hepatitis with accelerated progression to graft cirrhosis may be observed. Of concern, recent reports suggest that the outcome of LT for HCV may have deteriorated in recent years. Determinants of rate of progression to cirrhosis in the immunocompetent non-transplant patient are well defined, and the most powerful determinant is patient age at the time of infection. Following LT for HCV, recipient age does not affect outcome of HCV reinfection. However, the impact of donor age on graft fibrosis progression rate following LT has not been examined. Methods: We have examined post-transplant biopsies to assess histological activity, including fibrosis stage (scored 0-6 units, 6 representing established cirrhosis), and to calculate fibrosis progression rates in 101 post-transplant specimens from 56 HCV infected LT patients. Univariate and multivariate analyses examined the impact of parameters including recipient and donor age and sex on fibrosis progression rate, and on predicted time to cirrhosis. Results: For the cohort, median fibrosis progression rate was 0.78 units/year, and median interval from transplantation to development of cirrhosis was 7.7 years. In multivariate analysis, donor age (not recipient age) was a powerful determinant (p=0.02) of fibrosis progression rate. When the liver donor was younger than 40 years, median progression rate was 0.6 units/year and interval to cirrhosis was 10 ears. When the donor was aged 50 years or more, median progression rate was 2.7 units/year and interval to cirrhosis only 2.2 years. During the observation period there has been a significant increase in donor age (p=0.01) but date of transplantation per se is not a determinant of progression rate when included in multivariate analyses. Conclusions: Donor age has a major influence on graft outcome following transplantation for HCV. The changing organ donor profile will affect the long term results of LT for HCV. These observations have important implications for donor liver allocation.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [21] Recurrence and accelerated progression of hepatitis C following liver transplantation
    Bernard, PH
    Le Bail, B
    Rullier, A
    Trimoulet, P
    Neau-Cransac, M
    Balabaud, C
    Bioulac-Sage, P
    SEMINARS IN LIVER DISEASE, 2000, 20 (04) : 533 - 538
  • [22] Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
    Neumann, UP
    Berg, T
    Harren, M
    Langrehr, JM
    Neuhaus, P
    LIVER TRANSPLANTATION, 2003, 9 (06) : C33 - C33
  • [23] Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
    Walter, T.
    Dumortier, J.
    Scoazec, J.
    Boillot, O.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S181 - S181
  • [24] Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
    Feray, C
    JOURNAL OF HEPATOLOGY, 2004, 41 (05) : 862 - 863
  • [25] Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C.
    Mutimer, DJ
    Gunson, BK
    Chen, J
    Berenguer, J
    Neuhaus, P
    Castaing, D
    Garcia-Valdecasas, JC
    Salizzoni, M
    Adam, R
    Mirza, DF
    HEPATOLOGY, 2004, 40 (04) : 362A - 362A
  • [26] Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus
    Mutimer, DJ
    Gunson, B
    Chen, J
    Berenguer, J
    Neuhaus, P
    Castaing, D
    Garcia-Valdecasas, JC
    Salizzoni, M
    Moreno, GE
    Mirza, D
    TRANSPLANTATION, 2006, 81 (01) : 7 - 14
  • [27] Hepatic Fibrosis Progression in Patients with Hepatitis C Recurrence after Deceased Donor Orthotopic Liver Transplantation (DDLT)
    Meine, Mario H.
    Marroni, Claudio A.
    Brandao, Ajacio M.
    Fleck, Alfeu M., Jr.
    Osorio, Marcus V.
    Mucenic, Marcos
    Leipnitz, Ian
    Schlindwein, Eduardo S.
    Kiss, Guillermo
    Zanotelli, Maria L.
    Cantisani, Guido P. C.
    LIVER TRANSPLANTATION, 2011, 17 (06) : S206 - S206
  • [28] THE IMPACT OF DONOR AND RECIPIENTS SINGLE NUCLEOTIDE POLYMORPHISMS OF LIVING FIBROSIS PROGRESSION IN LIVING LIVER TRANSPLANTATION FOR HEPATITIS C
    Miyaaki, H.
    Ichikawa, T.
    Taura, N.
    Miuma, S.
    Shibata, H.
    Honda, T.
    Nakaoa, K.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S307 - S307
  • [29] Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression
    Toniutto, Pierluigi
    Minisini, Rosalba
    Fabris, Carlo
    De Feo, Tullia
    Marangoni, Francesca
    Burlone, Michela
    Avellini, Claudio
    Bitetto, Davide
    Fornasiere, Ezio
    Fumolo, Elisa
    Baccarani, Umberto
    Pirisi, Mario
    CLINICAL TRANSPLANTATION, 2009, 23 (02) : 184 - 190
  • [30] Aspirin reduces liver fibrosis progression in hepatitis C recurrence after liver transplantation
    Poujol-Robert, Armelle
    Boelle, Pierre-Yves
    Conti, Filomena
    Durand, Francois
    Duvoux, Christophe
    Wendum, Dominique
    Paradis, Valerie
    Mackiewicz, Vincent
    Chazouilleres, Olivier
    Poupon, Raoul
    HEPATOLOGY, 2013, 58 : 237A - 238A